Highlights Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq Other stock markets 21:00:00 07/06/2024 BST			5-day change	1st Jan Change
27.77 ^USD	-2.73%		-1.52%	-12.78%

06-04	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT
06-03	Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	06-03	MT
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	06-03	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	06-02	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	06-01	CI
Genmab A/S Reaffirms Financial Guidance for 2024	05-21	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	05-20	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	05-15	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	05-14	CI
GENMAB : A good start to 2024; guidance unchanged	05-03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	05-03	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	05-02	MT
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.	05-02	CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.	05-02	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	04-30	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	04-29	CI
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	04-16	MT
Health Care Slips on Risk Bias -- Health Care Roundup	04-11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	04-03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	04-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm